Sign in

Derek J. Maetzold

Founder, President, Chief Executive Officer (CEO) at CASTLE BIOSCIENCES
Board
Since September 2007
Age
63 years
Education
Holds a B.S. degree in Biology from George Mason University and has completed additional coursework at the University of Calgary Health Sciences Center and the MBA program at the University of California, Riverside.
Tenure
Founded CSTL in September 2007 and has served as its President and Chief Executive Officer (CEO) since its inception.

Also at CASTLE BIOSCIENCES

FS
Frank Stokes
Chief Financial Officer
KMO
Kristen M. Oelschlager
Chief Operating Officer
TWJ
Tobin W. Juvenal
Chief Commercial Officer

About

The executive holds a strong academic background, having earned a B.S. degree in Biology from George Mason University and completed further studies at the University of Calgary Health Sciences Center as well as the MBA program at the University of California, Riverside.

He founded CSTL in September 2007 and has served as its President and Chief Executive Officer (CEO) since inception, contributing significantly to the development and commercialization of diagnostic tests, particularly in the areas of oncology and dermatology.

Prior to launching CSTL, he gained extensive leadership experience in the pharmaceutical and healthcare sectors through roles at organizations such as Encysive Pharmaceuticals, Schering-Plough Corporation, Integrated Communications, Amylin Pharmaceuticals, and Sandoz Pharmaceuticals, while also contributing his expertise as a board member for entities including PreludeDx and IMPACT Melanoma.

$CSTL Performance Under Derek J. Maetzold

Past Roles

OrganizationRoleDate RangeDetails
Encysive PharmaceuticalsLeadership RoleN/AContributed to the discovery, development, and commercialization of diagnostic tests and co-invented technologies
Schering-Plough Corporation (now Merck)Leadership RoleN/ARole not detailed
Integrated CommunicationsLeadership RoleN/ARole not detailed
Amylin PharmaceuticalsLeadership RoleN/ARole not detailed
Sandoz Pharmaceuticals (now a division of Novartis)Leadership RoleN/ARole not detailed

External Roles

OrganizationRoleDate RangeDetails
PreludeDxDirectorN/AActive role outside CSTL
Coalition for 21st Century MedicineDirectorN/AActive role outside CSTL
IMPACT MelanomaDirectorN/AActive role outside CSTL

Fixed Compensation

Data from  FY 2023
Component NameAmountPayment ScheduleAdditional Details
Base Salary$686,400 AnnualFixed annual cash compensation; increased by 4.0% from $660,000 in 2022
401(k) Matching Contributions$18,300 Per contribution periodMatches 100% of up to 6% of eligible compensation; maximum match for 2023 was $19,800
Financial Advisory Services$7,934 AnnualReimbursement for financial advisory services provided in 2023

Performance Compensation

Data from  FY 2023

Non-Equity Incentive Plan Compensation

MetricValueCitation
Performance BasisCorporate Performance Goals (100% weighting)
Threshold Level55.0%
Target Level100%
Maximum Level172.5%
Actual Corporate Performance137.0%
Base Salary Used for Calculation$686,400
Target Bonus Percentage95% of base salary
Target Bonus Amount$652,080
Actual Bonus Earned$893,350
Vesting ScheduleNone (cash bonus, no vesting)N/A
Grant Date / Fair Value / Stock PriceN/AN/A
Evaluation Period2023